HIF1A and neoplasm: It is known that metformin activates AMPK to downregulate glycolysis in tumor cells partially through inhibiting mTORC1 and HIF-1α, and it may impair glycolysis in Teff cells in a similar manner, weakening their anti-tumor immune response.